ArticleGland surgery2025
Clinical characteristics and outcomes of patients with intrathyroidal thymic carcinoma (ITC): a retrospective cohort study.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intrathyroidal thymic carcinoma (ITC) is an extremely rare type of thyroid cancer with very limited knowledge of its clinical characteristics and optimal treatment modalities. We aimed to assemble the largest ITC cohort to date for a better understanding. Methods: We collected 43 surgically-treated patients with ITC in a single Chinese tertiary center. Kaplan-Meier analysis and multivariate Cox regression analysis is performed to explore prognostic factors. Hazard ratio (HR) and 95% confidence interval (95% CI) were used to indicate the risk associated with the risk factors. Results: A total of 43 cases with ITC were included. Eighteen patients (41.9%) had cervical or mediastinal lymph node metastases, while 16 (37.2%) had distant metastasis at presentation. Ten patients with locally advanced disease received palliative resection and following adjuvant radiotherapy, but none of them showed local progression. After a median follow-up of 69 months, we observed a favorable prognosis with a 3- and 5-year progression-free survival (PFS) of 92.1% and 59.8%, and a 3- and 5-year disease-specific survival (DSS) of 97.0% and 93.1%, respectively. Multivariate analysis showed that palliative resection (HR =5.68, 95% CI: 1.48-21.76, P=0.01) and lateral lymph node metastasis (HR =12.27, 95% CI: 2.40-62.81, P=0.003) were independent risk factors of tumor progression. Partial response was achieved in two patients who received immunotherapy combined with targeted therapy or chemotherapy. Conclusions: Despite with an overall favorable survival, ITC is still prone to lymph node and distant metastasis. Lateral neck metastasis and incomplete tumor resection predicted a poorer outcome. Once achievable, radical surgery combined with radiotherapy should be performed to improve local control, while immunotherapy and targeted therapies are potentially effective in advanced disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.